Insulet claims EOFlow copied patch-pump design in patent suit by Elise Reuter for, 15 August 2023.

Insulet claims that EOFlow’s EOPatch insulin pump violates three of the patents for its Omnipod patch pump and that the product designs “are practically identical.” The company filed the lawsuit on Aug. 3 in the U.S. District Court for the District of Massachusetts.  EOFlow, which is headquartered in South Korea, makes its EOPatch insulin pump and a paired controller device. It filed for 510(k) clearance in December.

Insulet alleges that when EOFlow was founded in 2011, it started out with a patch pump that used a different technology than Omnipod to deliver insulin, but around 2016, “EOFlow pivoted and launched a plan to brazenly copy Insulet’s Omnipod System.”  Insulet claims EOPatch’s exterior design looks “strikingly similar” to its product. It also alleges many of the interior components are similar. While EOPatch uses a different type of actuator than Omnipod, “nearly every other aspect of the EOPatch pumping mechanism is substantially identical to Insulet’s Omnipod product,” according to the lawsuit. 

Insulet is seeking double damages for willful and malicious appropriation, a “reasonable royalty” and attorney’s fees. It also seeks a permanent injunction barring the sale of products containing or derived from its trade secrets. In March, a court in Germany issued a preliminary injunction against EOFlow based on a separate patent case, Insulet CEO Jim Hollingshead

Read more:  Insulet claims EOFlow copied patch-pump design in patent suit

Amazon Pharmacy expands insulin manufacturer coupons by Rebecca Pifer for, 15 August 2023.

Amazon added more than 15 new manufacturer-sponsored coupons for insulin brands and diabetes care products to its online pharmacy. The additions bring Amazon’s manufacturer coupons that are automatically applied during check-out for eligible customers to 36. The new coupons include some of the most commonly prescribed products from drugmakers including Novo Nordisk, Eli Lilly and Sanofi, including insulin vials, pens, and continuous glucose monitors.

Drug manufacturers offer coupons for brand name medications to reduce out-of-pocket costs on drugs, which can be prohibitively expensive. But coupons can be hard to find and use — one study cited by Amazon found patients only used the coupons 15% of the time they were available. Amazon says its goal in offering the coupons is to increase savings for Amazon Pharmacy users.

The coupons can’t be used in addition to its generics saving program RxPass or the Prime prescription savings benefit. Patients covered under government programs like Medicare or Medicaid aren’t eligible for the coupons.

Read more:  Amazon Pharmacy expands insulin manufacturer coupons

Want to see a real-life FDA 510(k) Decision Summary for a new insulin pump?  510(k) SUBSTANTIAL EQUIVALENCE  DETERMINATION DECISION SUMMARY: DEKA ACE Pump System

The DEKA ACE Pump System is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin, ages 13 and above. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single-patient, home use, and requires a prescription.

Conclusion: The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.

Lilly Completes Acquisition of Sigilon Therapeutics by Eli Lilly and Company, posted by, 14 August 2023.

Eli Lilly and Company announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes.

“Make life better – that’s the phrase that guides everything we do at Lilly,” said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity, and cardiometabolic research at Lilly. “We are excited to welcome our new colleagues from Sigilon to Lilly; together, we will strive to provide solutions for people living with type 1 diabetes that absolves them of constant disease management, and advance Sigilon’s technology for patients.”

Read more:  Lilly Completes Acquisition of Sigilon Therapeutics

Insulin human by Oramed Pharmaceuticals for Type 1 Diabetes by GlobalData and published by, 14 August 2023.

Insulin human is under clinical development by Oramed Pharmaceuticals and is currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.  Insulin human (ORMD-0801) is under development for the treatment of NASH (NonAlcoholic SteatoHepatitis), type 1 diabetes, and type 2 diabetes. The drug candidate is administered through an oral route as a capsule. It is based on POD (Protein Oral Delivery) technology.

Oramed Pharmaceuticals is a pre-clinical pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes and orally ingestible capsules for delivery of other polypeptides.

Read more:  Insulin Human by Oramed Pharmaceuticals for Type 1 Diabetes

How Antidepressants Impact Diabetes by April Hopcroft for, 14 August 2023. 

Research shows that some antidepressants may improve blood sugar, while others cause it to spike. Many antidepressants may lead to weight gain as a side effect.

Antidepressants that raise blood sugar

        • Cymbalta (duloxetine)
        • Zoloft (sertraline)
        • Remeron (mirtazapine)
        • Luvox (fluvoxamine)
        • Paxil (paroxetine)

Antidepressants linked to lower blood sugar

        • Prozac (fluoxetine)
        • Lexapro (escitalopram)
        • Celexa (citalopram)
        • Savella (milnacipran)

Read more: How Antidepressants Impact Diabetes

Screen for cannabis hyperemesis syndrome for cannabis users with DKA symptoms by Michael Monostra for, 16 August 2023.

People with type 1 diabetes who use cannabis and present at a hospital with diabetic ketoacidosis symptoms may have hyperglycemic ketosis related to cannabis hyperemesis syndrome.  In a presentation at the Association of Diabetes Care and Education Specialists annual meeting, Halis Kaan Akturk, MD, associate professor of medicine and pediatrics at University of Colorado’s Barbara Davis Center for Diabetes, said hyperglycemic ketosis related to cannabis hyperemesis syndrome is commonly misdiagnosed as diabetic ketoacidosis and gastrointestinal symptoms are contributed to diabetic gastroparesis among adults with type 1 diabetes and leads to patients being misdiagnosed and mistreated in hospitals. Akturk said measuring pH and bicarbonate levels can diagnose most cases of hyperglycemic ketosis related to cannabis hyperemesis syndrome, but providers must be aware and screen for this condition.

Read more: Screen for cannabis hyperemesis syndrome for cannabis users with DKA symptoms

Taking a Look at Sexual Dysfunction in Females with T1D by Jennifer Smith for, August 2023.

Females with type 1 diabetes have many hormonal shifts to navigate throughout their life. The unfortunate thing is that most are not educated on the natural course of the change in these hormones as we age. When you add type 1 diabetes to this it can mean a host of things are happening without definition or acknowledgement that these are normal changes. Also lacking is information about how to adjust to maintain healthy glucose levels. Lack of healthy management of glucose levels can lead to complications in various areas of the body such as eyes, kidneys, blood vessels and in nerves around the body. With this as a consideration, I have found working with many people that the topic of sexual dysfunction (SD) is poorly discussed.

Recent research on this topic was published in Diabetic Medicine Journal. Paring the research down to just a few eligible studies showed that a female with T1D is THREE times more likely to experience SD compared to those without diabetes. The fact that females struggle with this, yet it is not addressed well indicates that there may be psychosocial factors influencing the discussion but also a lack of information or assessment from the clinician.

Share This
Skip to content